Dental laser supplier BIOLASE Inc (NASDAQ:BIOL) reported on Tuesday the receipt of US the Food and Drug Administration (FDA) regulatory clearance for the Epic Hygiene laser for Laser Bacterial Reduction (LBR) therapy indication.
US FDA approval for the company's Epic Hygiene laser allows for the early management of periodontal disease utilizing laser light energy to reduce bacteria and thus decreasing inflammation and enhancing periodontal health.
Designed by dental hygienists, the Epic Hygiene laser provides the dental hygienist community with more access to the advantages of laser technology as well as allows to perform gentler, highly effective treatments for bacterial reduction and managing periodontal disease.
The company stated that the Epic Hygiene laser has received clearance for the removal of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval